# A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)

Source: https://onco.cc/trials/nct06163430/  
OnCo record `nct06163430` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TERN-701 in chronic myeloid leukaemia, run by Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), now recruiting.

## Summary

A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL) is a phase 1/2 interventional study registered as NCT06163430 by Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), with 180 participants planned, started 2024-03-26 and due to reach its primary completion in 2029-11-30. Interventions recorded: TERN-701.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06163430
- Phase: 1/2
- Setting: A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia
- Sponsor: Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Enrolled: 180

## Sources

- ClinicalTrials.gov NCT06163430: https://clinicaltrials.gov/study/NCT06163430

## Connected records

- cancers: [Chronic myeloid leukaemia (CML)](https://onco.cc/cancers/cml/)

---
JSON: https://onco.cc/api/v1/entities/nct06163430.json